https://www.selleckchem.com/
Histological, immunohistochemical, mRNA sequencing and QRT-PCR studies were performed on tissue-biopsies. EGCG reduced mast cells at weeks-4 and 8 by gene and protein analyses (p less then 0.01). Group 1 was superior to other groups (p less then 0.01) in both clinical (blood flow) and laboratory parameters (elastin and immune marker expression). Additionally, there was down-regulation of angiogenic-markers by mRNA-sequencing and of CD31 and VEGF-A at weeks-4 and 8 (p less then 0.01) by immunohistochemistry and at week-4 (p less then 0.05) by QRT-PCR. EGCG i
Like
Comment
Share
